ArticleBMC pediatrics2026
Clinical profile, survival outcomes, and predictors of mortality in neonates with persistent pulmonary hypertension: a follow-up study from Hawassa, Ethiopia.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPersistent pulmonary hypertension of the newborn (PPHN) is a failure of normal fetal-to-neonatal circulatory transition. Evidence from low-resource settings remains limited. This study evaluated clinical characteristics, treatment outcomes, mortality predictors, and time to clinical and echocardiographic resolution among neonates with PPHN at a tertiary hospital in Hawassa, Ethiopia. METHODOLOGY: A retrospective follow-up study was conducted from July 1 to September 30, 2025, among 115 neonates admitted to the NICU of Hawassa University Comprehensive Specialized Hospital with PPHN diagnosed between June 2022 and June 2025. Clinical profiles were described using frequencies and percentages. Kaplan–Meier survival analysis and log-rank tests compared survival between severe and non-severe PPHN. Cox proportional hazards modeling identified predictors of mortality. Mann–Whitney U tests assessed differences in time to clinical and echocardiographic resolution.
resultsOf 115 neonates, 26.1% were delivered by cesarean section, 55.7% were term, and 51.3% had normal birth weight. Common etiologies included early-onset neonatal sepsis (74.8%), meconium aspiration syndrome (55.7%), and respiratory distress syndrome (30.4%). Severe PPHN, initially managed with sildenafil, was present in 89.6% of neonates; 20.9% required a saline bolus, and 20% required inotropic support. Over a median follow-up of 38 days (IQR: 8–45), mortality was 28.7%. Predictors of mortality included perinatal asphyxia (AHR: 2.4; 95% CI: 1.4–3.3), acute kidney injury (AHR: 1.9; 95% CI: 1.3–2.9), and need for inotropic support (AHR: 1.8; 95% CI: 1.3–2.5). Survival at 7, 30, and 60 days was lower in severe PPHN (78.8%, 60%, 60%) than in non-severe cases (100%, 97.1%, 97.1%; p < 0.001). Clinical resolution occurred earlier than echocardiographic resolution, with medians of 28 vs. 33 days overall; non-severe cases resolved faster clinically (8 vs. 28 days) and echocardiographically (9 vs. 33 days; p < 0.001).
conclusionWithin the study cohort, PPHN was most prevalent among term neonates, those with normal birth weight, and those delivered by cesarean section. Sepsis, meconium aspiration, and respiratory distress syndrome were common causes. Mortality was 28.7%, with perinatal asphyxia, acute kidney injury, and inotropic support identified as independent predictors. Early management and echocardiographic follow-up are essential, as echocardiographic resolution occurs later than clinical improvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.